Literature DB >> 20221574

[Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].

R Koch1, C A Sander.   

Abstract

Non-Hodgkin lymphomas (NHL) comprise a heterogeneous collection of lymphoproliferative malignancies. Follicular lymphoma (FL) is the second most common NHL sub-type. Over the last years, the introduction of the anti-CD20 monoclonal antibody rituximab has radically changed treatment of FL. After several large prospective randomized trials demonstrated prolongation of remission, current European indications for rituximab include the first-line treatment of patients with stage III-IV FL in combination with polychemotherapy such as CVP or CHOP. This paper discusses the treatment of primary nodal FL with secondary cutaneous involvement with rituximab as monotherapy without additional chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20221574     DOI： 10.1007/s00105-009-1902-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  8 in total

1.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

2.  Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Authors:  Stefano Sacchi; Samantha Pozzi; Luigi Marcheselli; Alessia Bari; Stefano Luminari; Francesco Angrilli; Francesco Merli; Daniele Vallisa; Luca Baldini; Maura Brugiatelli
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

Review 3.  [Malignant lymphoma in adults].

Authors:  M A Fridrik
Journal:  Dtsch Med Wochenschr       Date:  2008-10-01       Impact factor: 0.628

4.  Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.

Authors:  Thomas E Witzig; Allen M Vukov; Thomas M Habermann; Susan Geyer; Paul J Kurtin; William R Friedenberg; William L White; Haji I Chalchal; Patrick J Flynn; Thomas R Fitch; Debra A Welker
Journal:  J Clin Oncol       Date:  2005-01-18       Impact factor: 44.544

5.  Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

Authors:  P Colombat; G Salles; N Brousse; P Eftekhari; P Soubeyran; V Delwail; E Deconinck; C Haïoun; C Foussard; C Sebban; A Stamatoullas; N Milpied; F Boué; B Taillan; P Lederlin; A Najman; C Thièblemont; F Montestruc; A Mathieu-Boué; A Benzohra; P Solal-Céligny
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  Rituximab in indolent lymphoma: the single-agent pivotal trial.

Authors:  P McLaughlin; F B Hagemeister; A J Grillo-López
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

7.  Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.

Authors:  K Kerl; C Prins; J H Saurat; L E French
Journal:  Br J Dermatol       Date:  2006-12       Impact factor: 9.302

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.